NAPWA

The annual conference of the Australasian Society for HIV Medicine (ASHMAustralasian Society for HIV Medicine. The peak Australasian organisation representing the medical and health sector in HIV/AIDS and related areas. ) was held in Melbourne in November. This article summarises some key developments. read more »

Finding effective treatment options for people who have taken many treatments and have multiple resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant.. mutations continues to be a significant challenge for HIV clinicians, and their patients. read more »

HIV-related news in brief from the December 2006 edition of Positive Living. read more »

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports. read more »

Non-nucleosides are a powerful option for treating HIV, but cross-resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant.. can mean you only get one bite of the cherry. This is the final instalment in a three-part series looking at key drug classesA group of anti-HIV drugs with the same target of action. Anti-HIV drug classes include nucleoside analogue reverse transcriptase inhibitors, protease inhibitorsA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate. and non-nucleoside analogue reverse transcriptase inhibitors, as well as several others. Combining drugs from three or more classes is the basis of Highly Active AntiretroviralA medication or other substance which is active against retroviruses such as HIV. Therapy (HAARTHighly Active AntiRetroviral Therapy ??? aggressive treatment of HIV infection using several different drugs together.).. read more »

What is the place of T-20 in the spectrum of HIV treatment, and when is the best time to start treatment on T-20? These were among the questions considered at a meeting in Sydney on Saturday 8 April. read more »

With the SMART trial making treatment interruptions a much less attractive option for people with HIV, we take a look at one man’s experience of taking a break from treatments. read more »

Nucleoside analoguesA type of anti-HIV drug that works by inhibiting a stage of the HIV life cycle called reverse transcription. Non-nucleosides work in a similar way, but are chemically different. are the backbone of successful anti-HIV treatments. This article examines some of the issues involved in selecting the best nucleoside backbone. read more »

Thirty-two quick and easy strategies to help you take your medications on time. read more »

Why is adherence – taking your antiretroviralA medication or other substance which is active against retroviruses such as HIV. medications on time and not missing doses – such a big deal? read more »